Figure 3.

Treatment trends in the rheumatoid arthritis (RA) patients receiving a second biologic or targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD), stratified by body mass index (n = 1546). The inner circle illustrates the first b/tsDMARD, and for each corresponding initial drug, the bars indicate the second b/tsDMARD treatment. Only patients with recorded second treatments are represented. The number of patients for each drug sequence is mentioned by each bar. Complementary data are provided in Supplementary Table S4. Abbreviations: ada—adalimumab; eta—etanercept; inf—infliximab; cer—certolizumab; gol—golimumab; rit—rituximab; aba—abatacept; toc—tocilizumab; tof—tofacitinib.